SCHEMBL7797902

SCHEMBL7797902

Cc1cc(C)c(C)c(OCCCC(=O)OCC(Cl)(Cl)Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
HTT P42858 2/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 1/20 0.39
CDC7 O00311 1/20 0.38
MARK3 P27448 1/20 0.38
AXL P30530 1/20 0.38
FRK P42685 1/20 0.38
BLK P51451 1/20 0.38
NEK4 P51957 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7799043 0.85 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL7795236 0.80 MEN1 (0.40) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL7795191 0.78 ALDH1A1 (0.66) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL508579 0.69 DGKA (0.41) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL10105403 0.69 TSHR (0.40) ALDH1A1MEN1KMT2ATSHRMAPT
SCHEMBL11337474 0.68 HTR7 (0.56) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL4746677 0.67 L3MBTL1 (0.55) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL18644548 0.67 L3MBTL1 (0.58) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL9095809 0.66 DGKA (0.50) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL10749843 0.66 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010012901-A1 Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2001-08-09 US disclosed
US-6225480-B1 FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-01 US disclosed
EP-0948480-A1 SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-13 EP disclosed
WO-1998029386-A1 SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010012901-A1 Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis H1-0, H1-2, ASH2L ALDH1A1 894/4885KDM4E 1242/4885SMN1; SMN2 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.